Psychiatry Search
Psychiatry Psychiatry
alzheimer's%20disease%20-and-%20dementia
ALZHEIMER'S DISEASE AND DEMENTIA
Treatment Guideline Chart
Dementia is a clinical syndrome characterized by impairment of multiple higher cortical functions that include memory, orientation, thinking, comprehension, calculation, capacity for learning, language, judgment,  executive function and visuo-spatial function. It is usually accompanied or preceded by deterioration in emotional control, social behavior or motivation.
Alzheimer's disease is the most common cause of dementia. Sporadic cases usually present after >60 year while familial types are rare and present in <60 year of age (early-onset dementia).
Short-term memory loss is the most common early symptom. Other spheres of cognitive impairment manifest after several years.

Alzheimer's Disease and Dementia References

  1. Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2010;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x. Accessed 15 Mar 2011. PMID: 20500802
  2. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry. 1997 May;154(Suppl 5):001-39. PMID: 9140238
  3. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul;69(5):459-469. PMID: 17664405
  4. Bain LJ. A review of the "State of the Art" on mild cognitive impairment: the fourth annual symposium. Alzheimers Dement. 2006 Jul;2(3):246-256. PMID: 19595894
  5. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract. 2003 Apr;57(3):219-223. PMID: 12723727
  6. Delagarza VW. Pharmacologic treatment of Alzheimer's disease: an update. Am Fam Physician. 2003 Oct;68(7):1365-1372. PMID: 14567491
  7. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003 Mar;11(2):131-145. PMID: 12611743
  8. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1154-1166. PMID: 11342679
  9. Douglas S, James I, Ballard C. Non-pharmacological interventions in dementia. Adv Psychiatr Treat. 2004;10:171-179
  10. Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20:192-197. PMID: 16088144
  11. Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003 Jun;25(6):1765-1782. PMID: 12860497
  12. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002 Apr;359(9314):1283-1290. PMID: 11965273
  13. Gauthier S, Herrmann N, Ferreri F, et al. Use of memantine to treat Alzheimer's disease. CMAJ. 2006 Aug;175(5):501-502. PMID: 16940271
  14. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010 Oct;17(10):1236-1248. doi: 10.111/j.1468-1331.2010.03040.x. PMID: 20831773
  15. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2003(1)
  16. Ihl R, Bachinskaya N, Korczyn A, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2010 Nov;26(11):1186-1194. doi: 10.1002/gps.2662. PMID: 21140383
  17. Ihl R, Frolich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry. 2011 Feb;12(1):002-32. PMID: 21288069
  18. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2000;4:CD002854. doi: 10.1002/14651858.CD002854. PMID: 11034775
  19. Lanctot KL, Hermann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003 Sep;169(6):557-564. PMID: 12975222
  20. Kasper S, Schubert H. Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability. Fortschr Neurol Psychiatr. 2009 Sep;77(9):494-506. doi: 10.1055/s-0028-1109504. Accessed 04 Apr 2011. PMID: 19621278
  21. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1143-1153. PMID: 11342678
  22. Lippa CF, Duda JE, Grossman H, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007 Mar;68(11):812-819. PMID: 17353469
  23. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999 Nov;341(22):1670-1679. PMID: 10572156
  24. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1133-1142. PMID: 11342677
  25. Roman GC. Rivastigmine for subcortical vascular dementia. Expert Rev Neurother. 2005 May;5(3):309-313. PMID: 15938663
  26. Wei ZH, He QB, Wang H, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease [abstract]. J Neural Transm. 2007;114(5):629-634. http://www.ncbi.nlm.nih.gov. Accessed 15 Mar 2011. PMID: 17318304
  27. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia [abstract]. Drugs & Aging. 2009 Nov;26(11):893-915. doi: 10.2165/11203320-000000000-00000. Accessed 15 Mar 2011. PMID: 19848437
  28. Ubhi K, Rockenstein E, Doppler E, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol. 2009 Jun;117(6):699-712. PMID: 19252918
  29. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010 Mar;10(14):001-12. http://www.biomedcentral.com. Accessed 04 Apr 2011. PMID: 20236541
  30. MedWormhttp://www.medworm.com/rss/index.php/Neurology/25/http://www.medworm.com/rss/medicalfeeds/specialities/Neurology.xml
  31. MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
  32. Kuljis R. Alzheimer disease. eMedicine. http://emedicine.medscape.com. 2007.
  33. Ministry of Health Singapore. Clinical practice guidelines: dementia. MOH (Singapore). http://www.moh.gov.sg. 2007. Accessed 15 Mar 2011.
  34. Academy of Medicine of Malaysia, Ministry of Health of Malaysia. Clinical practice guidelines for management of dementia. Academy of Medicine of Malaysia. http://www.acadmed.org.my. Jun 2003.
  35. National Collaborating Centre for Mental Health. Dementia: supporting people with dementia and their carers in health and social care. National Clinical Practice guideline No. 42. NICE. http://www.nice.org.uk. 2007. Accessed 15 Mar 2011.
  36. National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. Review of NICE technology appraisal guidance 111. NICE. http://www.nice.org.uk. Sep 2007.
  37. National Collaborating Centre for Mental Health. Dementia: supporting people with dementia and their carers in health and social care. National Clinical Practice guideline No. 42. NICE. http://www.nice.org.uk. 2011. Accessed 05 Apr 2011.
  38. American Psychiatric Association. Guideline watch: practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Psychiatryonline. http://www.psychiatryonline.org. Apr 2006.
  39. Fisher Center for Alzheimer’s Research Foundation. New concerns raised about vitamin E and Alzheimer’s. http://www.alzinfo.org. 29 Nov 2004.
  40. Scottish Intercollegiate Guidelines Network. Management of patients with dementia: national clinical guideline. SIGN. http://www.sign.ac.uk. Feb 2006.
  41. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias [2nd ed]. Psychiatryonline. http://www.psychiatryonline.com. Oct 2007. Accessed 15 Mar 2011.
  42. Rabins P, Rovner B, Rummans T, et al. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Psychiatryonline. http://psychiatryonline.org. Oct 2014. Accessed 18 Aug 2015.
  43. The Hong Kong Geriatrics Society. Treatment guideline and practical tips in using cholinesterase inhibitors and NMDA receptor antagonist. In: Wai AYT. Practical Manual of Neurocognitive Disorders in Older Adults; 2014 Jun:162-167.
  44. Prince M, Wilmo A, Guerchet M, et al. World Alzheimer Report 2015 - the global Impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International. http://www.alz.co.uk. 2015. Accessed 26 Apr 2017.
  45. Keene CD, Montine TJ, Kuller LH. Epidemiology, pathology and pathogenesis of Alzheimer disease. UpToDate. https://www.uptodate.com. Jan 2018. Accessed 10 Jun 2019.
  46. World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. WHO. https://www.who.int. 2019. Accessed 10 Jun 2019.
  47. Farlow MR. Clinical features and diagnosis of dementia with Lewy bodies. UpToDate. https://www.uptodate.com. Aug 2017. Accessed 12 Apr 2021.
  48. Larson EB. Evaluation of cognitive impairment and dementia. UpToDate. https://www.uptodate.com. May 2019. Accessed 10 Jun 2019.
  49. Press D, Alexander M. Treatment of dementia. UpToDate. https://www.uptodate.com. Jan 2018. Accessed 10 Jun 2019.
  50. Press D, Alexander M. Management of neuropsychiatric symptoms of dementia. UpToDate. https://www.uptodate.com. Nov 2018. Accessed 10 Jun 2019.
  51. Wolk DA, Dickerson BC. Clinical features and diagnosis of Alzheimer disease. UpToDate. https://www.uptodate.com. Nov 2018. Accessed 10 Jun 2019.
  52. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan;90(3):126-135. doi: 10.1212/WNL.0000000000004826. PMID: 29282327
  53. Academy of Medicine Malaysia, Ministry of Health Malaysia. Management of dementia (2nd edition). Academy of Medicine of Malaysia. http://www.acadmed.org.my. 2009. Accessed 10 Jun 2019.
  54. Cognitive Decline Partnership Centre. Clinical practice guidelines and principles of care for people with dementia. Australian Clinical Practice Guidelines. http://www.clinicalguidelines.gov.au. 2016.
  55. Epperly T, Dunay MA, Boice JL. Alzheimer disease: Pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physician. 2017 Jun;95(12):771-778. PMID: 28671413
  56. Farlow MR, Small GW, Quarg P, et al. Efficacy of rivastigmine in Alzheimer’s disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20(2-3):192-197. doi: 10.1159/000087301. Accessed 19 Jun 2019. PMID: 16088144
  57. Larson EB. Risk factors for cognitive decline and dementia. UpToDate. https://www.uptodate.com. Dec 2017. Accessed 10 Jun 2019.
  58. Lorentz WJ, Scanlan JM, Borson S. Brief screening tests for dementia. Can J Psychiatry. 2002 Oct;47(8):723-733. doi: 10.1177/070674370204700803. PMID: 12420650
  59. Ministry of Health Singapore. Dementia: MOH clinical practice guidelines 1/2013. Ministry of Health Singapore. http://www. moh.gov.sg. Apr 2013. Accessed 19 Jun 2019.
  60. National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. NICE technology appraisal guidance 217. NICE. http://www.nice.org.uk. Mar 2011. Accessed 19 Jun 2019.
  61. Peterson R, Graff-Radford J. Alzheimer disease and other dementias. In: Daroff RB, Jankovic J, Mazziotta JC, et al. Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, Pennsylvania, USA: Saunders, Elsevier; 2016. http://dx.doi.org/10.1016/B978-0-323-28783-8.00095-8. :1380-1421.
  62. Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. UpToDate. https://www.uptodate.com. Mar 2018. Accessed 19 Jun 2019.
  63. Qui C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128. PMID: 19585947
  64. Reese TR, Thiel DJ, Cocker KE. Behavioral disorders in dementia: appropriate nondrug interventions and antipsychotic use. Am Fam Physician. 2016 Aug;94(4):276-282. PMID: 27548592
  65. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May;173(5):543-546. doi: 10.1176/appi.ajp.2015.173501. PMID: 27133416
  66. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012 Sep;19(9):1159-1179. doi: 10.1111/j.1468-1331.2012.03784.x. PMID: 22891773
  67. Frederiksen KS, Cooper C, Frisoni GB, et al. A European Academy of Neurology guideline on medical management issues in dementia. Eur J Neurol. 2020 Jul;0:1-16. doi: 10.1111/ene.14412.
  68. Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimer’s Dement. 2020;16:1182-1195. doi: 10.1002/alz.12105. Accessed 17 Nov 2020
  69. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug;396(10248):10248. doi: 10.1016/S0140-6736(20)30367-6. PMID: 32738937
  70. Smith E, Wright CB. Etiology, clinical manifestations, and diagnosis of vascular dementia. UpToDate. https://www.uptodate.com. 17 Nov 2020.
  71. Winslow BT, Onysko MK, Stob CM , et al. Treatment of Alzheimer disease. Am Fam Physician. 2011 Jun;83(12):1403-1412. PMID: 21671540
  72. National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults. NICE. https://www.nice.org.uk/. 19 Jul 2017. Accessed 12 Apr 2021.
  73. Engelhardt E, Tocquer C, Andre C, et al. Vascular dementia: diagnostic criteria and supplementary exams. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Part I. Dement Neuropsychol. 2011 Dec;5(4):251-263. doi: 10.1590/S1980-57642011DN05040003. PMID: 29213752
  74. Farlow MR. Prognosis and treatment of dementia with Lewy bodies. UpToDate. https://www.uptodate.com. 15 Apr 2020.
  75. Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin. 2007 Aug;25(3):741-vii. doi: 10.1016/j.ncl.2007.03.001. Accessed 12 Apr 2021. PMID: 17659188
  76. Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014 Aug;30(3):421-442. doi: 10.1016/j.cger.2014.04.001. Accessed 12 Apr 2021. PMID: 25037289
  77. Jellinger KA. Neuropathology of the Alzheimer’s continuum: update. Free Neuropathology. 2020 Nov;1:32. doi: 10.17879/freeneuropathology-2020-3050. Accessed 12 Apr 2021
  78. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017 Jul;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Accessed 12 Apr 2021. PMID: 28592453
  79. McVeigh C, Passmore P. Vascular dementia: prevention and treatment. Clin Interv Aging. 2006;1(3):229-235. doi: 10.2147/ciia.2006.1.3.229. PMID: 18046875
  80. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE. http://www.nice.org.uk/. 20 Jun 2018.
  81. Petersen RC. Mild cognitive impairment: epidemiology, pathology, and clinical assessment. UpToDate. https://www.uptodate.com. 10 Dec 2020. Accessed 12 Apr 2021.
  82. Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer Disease. Neurology. 2005 Sep;65(5):719-725. doi: 10.1212/01.wnl.0000173837.82820.9f. Accessed 12 Apr 2021. PMID: 16157905
  83. Smith EE, Barbar P, Field TS, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: guidelines for management of vascular cognitive impairment. Alzheimers Dement (NY). 2020 Nov;6(1):e12056. doi: 10.1002/trc2.12056. Accessed 12 Apr 2021. PMID: 33209971
  84. World Health Organization. Dementia. WHO. https://www.who.int/. 21 Sep 2020.
  85. Neikrug AB, Ancoli-Israel S. Sleep-wake disturbances and sleep disturbances in patients with dementia. UpToDate. https://www.uptodate.com. 24 Mar 2021.
  86. Press D, Alexander M. Prevention of dementia. UpToDate. https://www.uptodate.com. 07 Jan 2020.
  87. Shaji KS, Sivakumar PT, Rao GP, et al. Clinical practice guidelines for management of dementia. Indian J Psychiatry. 2018 Feb;60(Suppl 3):S312-S328. doi: 10.4103/0019-5545.224472. PMID: 29535467
  88. Smith E, Wright CB. Treatment of vascular cognitive impairment and dementia. UpToDate. https://www.uptodate.com. 21 Jul 2020.
  89. Tripathi M, Vibha D. Reversible dementias. Indian J Psychiatry. 2009 Jan;51(Suppl 1):S52-S55. PMID: 21416018
  90. U.S. Food & Drug Administration. FDA grants accelerated approval for Alzheimer’s disease treatment [Internet]. US FDA. https://www.fda.gov/. 2023 Jan 06.
  91. Meshkini M, Meshkini A, Sadeghi-Bazargani H. Use of neuroprotective agents for traumatic brain injury. Traumatic Brain Injury - Neurobiology, Diagnosis and Treatment: IntechOpen; 2019 Sep. doi: 10.5772/intechopen.85720.
  92. Cummings J, Aisen P, Apostolova LG, et al. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410. doi: 10.14283/jpad.2021.41. PMID: 34585212
  93. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023. http://dx.doi.org/10.14283/jpad.2023.30.
  94. Larson EB. Evaluation of cognitive impairment and dementia. UpToDate. https://www.uptodate.com/. 02 Nov 2022.
  95. Mendez MF. Mental status scales to evaluate cognition. UpToDate. https://www.uptodate.com/. 14 Apr 2023.
  96. Press D. Management of neuropsychiatric symptoms of dementia. UpToDate. https://www.uptodate.com/. 07 Apr 2022.
  97. Press D, Buss SS. Treatment of Alzheimer disease. UpToDate. https://www.uptodate.com/. 30 Sep 2021.
  98. U.S. Food & Drug Administration. FDA grants accelerated approval for Alzheimer’s drug [Internet]. US FDA. https://www.fda.gov/. 07 Jun 2021.
  99. U.S. Food & Drug Administration. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer’s Disease [Internet]. US FDA. https://www.fda.gov/. 11 May 2023.
  100. Wolk DA, Dickerson BC. Clinical features and diagnosis of Alzheimer disease. UpToDate. https://www.uptodate.com/. 08 Oct 2021.
  101. Hoerr R, Zimmermann A, Seitz F, et al. Single and repeated doses of EGb 761® do not affect pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects. Front Pharmacol. 2022 Apr;13:868843. doi: 10.3389/fphar.2022.868843. PMID: 35517810
  102. Kloft C, Hoerr R. EGb 761® does not affect blood coagulation and bleeding time in patients with probable Alzheimer's dementia-secondary analysis of a randomized, double-blind placebo-controlled trial. Healthcare (Basel). 2021 Dec;9(12):1678. doi: 10.3390/healthcare9121678. PMID: 34946404
  103. Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs R D. 2006;7(3):163-172. doi: 10.2165/00126839-200607030-00003. PMID: 16752942
Editor's Recommendations
Special Reports
MORE Special Reports arrow
Related Disease News
MORE Disease News arrow